COVID-19 has shown how Big Pharma is broken

Charlotte Kilpatrick of Salon writes about the motives that pharmaceutical companies have to invest in R&D for underfunded global health threats, such as coronaviruses.

In this piece, the author writes about the ways that pharmaceutical companies choose where to invest their money. Referencing a key finding from the 2021 Access to Medicine Index, Kilpatrick writes that in 2020, only 6 of 16 threatening pathogens identified by the WHO in 2016 were being researched by pharma companies.

Read the full article here.